Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

Breast

Volumn 24, Issue 3, 2015, Pages 182-190

  Diéras, Véronique ^a   Wildiers, Hans ^b   Jassem, Jacek ^c   Dirix, Luc Y ^d   Guastalla, Jean Paul ^e   Bono, Petri ^f   Hurvitz, Sara A ^g   Gonçalves, Anthony ^h   Romieu, Gilles ⁱ   Limentani, Steven A ^j   Jerusalem, Guy ^k   Lakshmaiah, K C ^l   Roché, Henri ^m   Sánchez Rovira, Pedro ⁿ   Pienkowski, Tadeusz ^o   Seguí Palmer, Miguel Ángel ^p   Li, Ai ^q   Sun, Yu Nien ^q   Pickett, Cheryl A ^q   Slamon, Dennis J ^q  

^a INSTITUT CURIE   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

^e CENTRE LÉON BÉRARD   (France)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ CENTRE VAL D AURELLE   (France)

^j LEVINE CANCER INSTITUTE   (United States)

^k UNIVERSITY OF LIÈGE   (Belgium)

^l KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^m INSTITUT CLAUDIUS REGAUD   (France)

ⁿ Allergy Section   (Spain)

^o European Health Centre Otwock (ECZO)   (Poland)

^p Hospital Universitari Parc Taulí   (Spain)

^q AMGEN INC   (United States)

more..

Author keywords

AMG 386; Bevacizumab; HER2 negative; Paclitaxel; Trebananib

Indexed keywords

BEVACIZUMAB; PACLITAXEL; PLACEBO; TREBANANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HYBRID PROTEIN;

ADULT; ALOPECIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BREAST CANCER; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DYSGEUSIA; DYSPHONIA; EPISTAXIS; FAINTNESS; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; IMMUNOGENICITY; LEUKOPENIA; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; AGED; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RECOMBINANT FUSION PROTEINS;

EID: 84937641865     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.11.003     Document Type: Article

References (27)

1. Oliner J., Min H., Leal J., Yu D., Rao S., You E., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
2. Saharinen P., Eklund L., Pulkki K., Bono P., Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 2011, 17:347-362.
3. Hashizume H., Falcon B.L., Kuroda T., Baluk P., Coxon A., Yu D., et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010, 70:2213-2223.
4. Huang H., Lai J.Y., Do J., Liu D., Li L., Del Rosario J., et al. Specifically targeting angiopoietin-2 inhibit angiogenesis, Tie2 expressing monocyte infiltration and tumor growth. Clin Cancer Res 2011, 17:1001-1011.
5. Huang J., Bae J.O., Tsai J.P., Kadenhe-Chiweshe A., Papa J., Lee A., et al. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int J Oncol 2009, 34:79-87.
6. Brufsky A.M., Hurvitz S., Perez E., Swamy R., Valero V., O'Neill V., et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. JClin Oncol 2011, 29:4286-4293.
7. Miles D.W., Chan A., Dirix L.Y., Cortes J., Pivot X., Tomczak P., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. JClin Oncol 2010, 28:3239-3247.
8. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. NEngl J Med 2007, 357:2666-2676.
9. Robert N.J., Dieras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. JClin Oncol 2011, 29:1252-1260.
10. Kumler I., Christiansen O.G., Nielsen D.L. Asystematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev 2014, 40:960-973.
11. Carpenter D., Kesselheim A.S., Joffe S. Reputation and precedent in the bevacizumab decision. NEngl J Med 2011, 365:e3.
12. D'Agostino R.B., Sr Changing end points in breast-cancer drug approval-the Avastin story. NEngl J Med 2011, 365:e2.
13. Coxon A., Bready J., Min H., Kaufman S., Leal J., Yu D., et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010, 9:2641-2651.
14. Herbst R.S., Hong D., Chap L., Kurzrock R., Jackson E., Silverman J.M., et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. JClin Oncol 2009, 27:3557-3565.
15. Mita A.C., Takimoto C.H., Mita M., Tolcher A., Sankhala K., Sarantopoulos J., et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010, 16:3044-3056.
16. Lu J.-F., Rasmussen E., Karlan B.Y., Vergote I.B., Navale L., Kuchimanchi M., et al. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol 2012, 69:1135-1144.
17. Karlan B.Y., Oza A.M., Richardson G.E., Provencher D.M., Hansen V.L., Buck M., et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. JClin Oncol 2012, 30:362-371.
18. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNatl Cancer Inst 2000, 92:205-216.
19. Collett D. Modelling Survival Data in Medical Research 2003, Chapman and Hall/CRC Press LLC, Boca Raton, FL. 2nd ed.
20. Brookmeyer R., Crowley J. Aconfidence interval for the median survival time. Biometrics 1982, 38:29-41.
21. Martin M., Roche H., Pinter T., Crown J., Kennedy M.J., Provencher L., et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011, 12:369-376.
22. Robert N.J., Saleh M.N., Paul D., Generali D., Gressot L., Copur M.S., et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 2011, 11:82-92.
23. Brufsky A., Hoelzer K., Beck T., Whorf R., Keaton M., Nadella P., et al. Arandomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. Clin Breast Cancer 2011, 11:211-220.
24. Monk B.J., Poveda A., Vergote I., Raspagliesi F., Fujiwara K., Bae D., et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014, 15:799-808.
25. Eskens F.A., Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006, 42:3127-3139.
26. Eatock M., Tebbutt N., Bampton C.L., Strickland A., Valladares-Ayerbes M., Swieboda-Sadlej A., et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol 2013, 24:710-718.
27. Sharma M.R., Stadler W.M., Ratain M.J. Randomized phase II trials: a long-term investment with promising returns. JNatl Cancer Inst 2011, 103:1093-1100.